Cholette François, Fabia Rissa, Harris Angela, Ellis Hannah, Cachero Karla, Schroeder Lukas, Mesa Christine, Lacap Philip, Arnold Corey, Galipeau Yannick, Langlois Marc-André, Colwill Karen, Gingras Anne-Claude, McGeer Allison, Giles Elizabeth, Day Jacqueline, Osiowy Carla, Durocher Yves, Hankins Catherine, Mazer Bruce, Drebot Michael, Kim John
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Heliyon. 2022 Sep;8(9):e10270. doi: 10.1016/j.heliyon.2022.e10270. Epub 2022 Aug 28.
The extent of the COVID-19 pandemic will be better understood through serosurveys and SARS-CoV-2 antibody testing. Dried blood spot (DBS) samples will play a central role in large scale serosurveillance by simplifying biological specimen collection and transportation, especially in Canada. Direct comparative performance data on multiplex SARS-CoV-2 assays resulting from identical DBS samples are currently lacking. In our study, we aimed to provide performance data for the BioPlex 2200 SARS-CoV-2 IgG (Bio-Rad), V-PLEX SARS-CoV-2 Panel 2 IgG (MSD), and Elecsys Anti-SARS-CoV-2 (Roche) commercial assays, as well as for two highly scalable in-house assays (University of Ottawa and Mount Sinai Hospital protocols) to assess their suitability for DBS-based SARS-CoV-2 DBS serosurveillance. These assays were evaluated against identical panels of DBS samples collected from convalescent COVID-19 patients ( = 97) and individuals undergoing routine sexually transmitted and bloodborne infection (STBBI) testing prior to the COVID-19 pandemic ( = 90). Our findings suggest that several assays are suitable for serosurveillance (sensitivity >97% and specificity >98%). In contrast to other reports, we did not observe an improvement in performance using multiple antigen consensus-based rules to establish overall seropositivity. This may be due to our DBS panel which consisted of samples collected from convalescent COVID-19 patients with significant anti-spike, -receptor binding domain (RBD), and -nucleocapsid antibody titers. This study demonstrates that biological specimens collected as DBS coupled with one of several readily available assays are useful for large-scale COVID-19 serosurveillance.
通过血清学调查和新冠病毒2型（SARS-CoV-2）抗体检测，能更好地了解新冠疫情的规模。干血斑（DBS）样本将在大规模血清学监测中发挥核心作用，因为它简化了生物样本的采集和运输，在加拿大尤其如此。目前缺乏来自相同DBS样本的多重SARS-CoV-2检测的直接对比性能数据。在我们的研究中，我们旨在提供BioPlex 2200 SARS-CoV-2 IgG（伯乐公司）、V-PLEX SARS-CoV-2 Panel 2 IgG（默克密理博公司）和Elecsys Anti-SARS-CoV-2（罗氏公司）商业检测方法，以及两种高度可扩展的内部检测方法（渥太华大学和西奈山医院方案）的性能数据，以评估它们在基于DBS的SARS-CoV-2 DBS血清学监测中的适用性。这些检测方法是针对从新冠康复患者（n = 97）和在新冠疫情之前接受常规性传播和血源感染（STBBI）检测的个体（n = 90）采集的相同DBS样本进行评估的。我们的研究结果表明，几种检测方法适用于血清学监测（敏感性>97%，特异性>98%）。与其他报告不同的是,我们没有观察到使用基于多种抗原共识的规则来确定总体血清阳性会提高检测性能。这可能是由于我们的DBS样本组由从具有显著抗刺突、抗受体结合域（RBD）和抗核衣壳抗体滴度的新冠康复患者采集的样本组成。这项研究表明，作为DBS采集的生物样本与几种现成的检测方法之一相结合，可用于大规模的新冠血清学监测。
